The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors
Japanese Journal of Clinical Oncology · 04.09.2024 · 54 (9) · 949-958
DOI: 10.1093/jjco/hyae067 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 20.05.2024. Verfasst von Taito Fukushima und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Immune checkpoint inhibitors have revolutionized cancer treatment by targeting the cytotoxic T lymphocyte antigen-4 and programmed death-1/ligand-1. Although immune checkpoint inhibitors show promising therapeutic efficacy, they often cause immune-related adverse events. Immune-related adverse events differ from the side effects of conventional chemotherapy and require vigilant monitoring. These events predominantly affect organs, such as the colon, liver, lungs, pituitary gland, thyroid and skin, with rare cases affecting the heart, nervous system and other tissues. As immune-related adverse events result from immune activation, indicating the reinvigoration of exhausted immune cells that attack both tumors and normal tissues, it is theoretically possible that immune-related adverse events may signal a better response to immune checkpoint inhibitor therapy. Recent retrospective studies have explored the link between immune-related adverse event development and clinical efficacy; however, the predictive value of immune-related adverse events in the immune checkpoint inhibitor response remains unclear. Additionally, studies have focused on immune-related adverse events, timing of onset and immunosuppressive treatments. This review focuses on pivotal studies of the association between immune-related adverse events and outcomes in patients treated with immune checkpoint inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
ORCID-Profile: Taito Fukushima, Satoshi Kobayashi
Zitieren
APA
Fukushima, T., Kobayashi, S., & Ueno, M. (2024). The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors. Japanese Journal of Clinical Oncology, 54(9), 949-958. https://doi.org/10.1093/jjco/hyae067
Vancouver
Fukushima T, Kobayashi S, Ueno M. The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors. Japanese Journal of Clinical Oncology. 2024;54(9):949-958. doi:10.1093/jjco/hyae067
BibTeX
@article{Fukushima2024,
author = {Fukushima, Taito and Kobayashi, Satoshi and Ueno, Makoto},
title = {The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors},
journal = {Japanese Journal of Clinical Oncology},
year = {2024},
volume = {54},
number = {9},
pages = {949--958},
doi = {10.1093/jjco/hyae067}
}
EUVIMED